A research team has developed a new class of protein-based MRI contrast agent that detects invasive lung cancer and metastatic disease at earlier stages than conventional imaging approaches.
Cardiovascular disease remains the leading cause of death across the EU. Yet prevention and early intervention can have a major impact – and this is precisely the ambition of the EU Safe Hearts Plan. At a high-level event at the European Parliament in Brussels in July, policymakers, clinicians, patients, and industry came together to explore how diagnostic imaging can contribute to this goal.
New research suggests that subtle markers during sleep – such as nocturnal micro-awakenings – may yield early clues to a greater genetic risk of developing Alzheimer’s disease.
A diffusion MRI metric can detect changes in white matter tracts not visible on conventional MRI – this could help identify early abnormalities in the brain associated with Alzheimer’s disease.
Chemotherapy of many childhood cancers leaves specific traces in the DNA, a new study finds. These changes could help clinicians spot treatment resistance earlier, before cancer returns or spreads.
A promising predictive model could help women calculate their personal risk for breast cancer, based on non-genetic, genetic and mammographic risk factors, and greatly improve early detection efforts.
Some arrhythmias, particularly short episodes of atrial fibrillation, may go unnoticed until they cause serious health problems. Novel wearable technology aims to pick up on these hidden signs.
The presence of certain bacteria in the gut microbiota, and fluctuations in a person’s metabolism, have been identified as potential biomarkers for type 2 diabetes years before its onset.
AI models can now assess breast cancer risk directly from changes in screening mammograms over time, a new study shows. This opens the door to a new era of dynamic breast cancer risk assessment.
Invasive fungal infections are silent, fast-moving, and notoriously hard to catch in time. The FUJIFILM Wako β-D-Glucan Test on the LIMUSAVE MT-7500 gives clinical laboratories a quantitative, LAL-based tool to detect (1→3)-β-D-glucan in serum or plasma – enabling earlier diagnosis where it matters most.
A simple, affordable urine test could detect early signs of lung cancer months, or even years, before symptoms appear, as well as monitor whether treatment is working and identify potential relapse.
Pancreas lesions are of diagnostic concern, as they may evolve into pancreatic cancer – but many never do. New research findings help explain how the transformation into a malignant state works.
Researchers have developed an electrochemical sensor that can detect pancreatic cancer in its early stages. The device offers a simpler, more affordable alternative to conventional tests, which are less accessible.
The incidence of colorectal cancer is rising among younger individuals, sometimes as early as their thirties. The research also shows the challenge of late diagnoses and calls for increased awareness.
New models help identify cardiovascular disease risk even before symptoms appear. The researcher's findings also indicate that the risk of heart failure is not evenly distributed across Europe.
By combining two specific markers from a standard cardiac CT scan, researchers were able to identify patients at the highest risk for future heart failure and death.
Not all precancerous lesions will develop into tumours, yet the majority are treated as if they were already breast cancer. A new marker could help identify the relevant cases and avoid overtreatment.
A compact LED module pairs UV-A, green and IR light with a matched photodiode to detect AGE autofluorescence — bringing biochemical risk screening to wearables and point of care testing.
Earlier detection, better outcomes: A new blood test for bowel cancer screening is designed to transform cancer outcomes by moving away from invasive or unpleasant methods.
